{"brief_title": "Phase II Randomized Study of Leuprolide Vs Oral Contraceptive Therapy Vs Leuprolide and Oral Contraceptive Therapy for Ovarian Hyperandrogenism", "brief_summary": "OBJECTIVES: I. Evaluate the beneficial effects of leuprolide depot, oral contraceptive therapy, and leuprolide/oral contraceptive therapy in the management of patients with ovarian hyperandrogenism.", "detailed_description": "PROTOCOL OUTLINE: This is a randomized study. Patients are randomly assigned to a 6-month course of leuprolide versus ethinyl estradiol/norethindrone (Ovcon 35) versus leuprolide plus Ovcon 35. Leuprolide is administered intramuscularly in depot form every 28 days.", "condition": "Hyperandrogenism", "intervention_type": "Drug", "intervention_name": "Ethinyl estradiol/norethindrone", "criteria": "PROTOCOL ENTRY CRITERIA: Disease Characteristics - Ovarian hyperandrogenism with Lorenzo hirsutism score 7 to 20, with or without severe acne - Serum hormone levels: Follicle-stimulating hormone no greater than 40 mIU/mL Luteinizing hormone no greater than 40 mIU/mL Testosterone 60 to 200 ng/dL Dehydroepiandrosterone sulfate no greater than 430 micrograms/dL 17-hydroxyprogesterone no greater than 3.3 ng/mL in follicular phase Prolactin no greater than 18 ng/dL - No adrenal or ovarian tumors Prior/Concurrent Therapy - At least 6 months since exogenous steroids At least 48 hours since drugs other than acetaminophen, ibuprofen, and aspirin Patient Characteristics - No malignancy, including the following carcinomas: Breast Cervix Ovary Uterus No other serious illness No cigarette smokers No nursing women No pregnancy within 6 months prior to entry", "gender": "Female", "minimum_age": "15 Years", "maximum_age": "40 Years", "healthy_volunteers": "No", "id": "NCT00004763.xml"}